On May 2, Dr. Chao Shoubai, former senior vice president of global biopharmaceuticals at AstraZeneca, officially joined the company as the chief operating officer.
On the morning of the same day, Dr. Wu Xiaobin, the former general manager of Pfizer China, was officially appointed as the general manager and president of the company in Baekje China.
In recent years, domestic pharmaceutical policies have been favorable, and global executives of multinational pharmaceutical giants have returned to China to join domestic innovative pharmaceutical companies. Behind this, the domestic pharmaceutical innovation environment is constantly maturing, and domestic pharmaceutical companies and markets also recognize that enterprises must accelerate research and development and innovation.
With the favorable policies of the series and the attraction of the market environment, more and more sea “sea returnees†talents, especially those with rich experience in innovative R&D and product internationalization, have returned to China to join the country. Fierce competition in the market.
In addition, pharmaceutical companies will gain new experience and practice as multinational pharmaceutical executives join in the development of these products, industrialization and management, as well as comprehensive talents who are familiar with domestic and foreign policies and regulations. These comprehensive talents will also help the development of domestic innovative pharmaceutical companies with the globalization of the pharmaceutical industry.
Since the second half of 2015, the policy environment of the domestic pharmaceutical industry has also undergone a series of changes. The entire industry is in a new period of change, including drug declaration (chemical drug registration classification reform), approval review (clinical test data self-examination and verification, Establish a priority review system), production and listing (the implementation of the pilot of the MAH system), and post-marketing (similar evaluation of generic drugs).
In October 2017, China subsequently issued the “Opinions on Deepening the Reform of the Examination and Approval System to Encourage the Innovation of Pharmaceutical Medical Devicesâ€, which is widely recognized as a programmatic document in the industry and is the “Thirty-six†to encourage the innovation and development of pharmaceutical medical devices. It is a milestone for the innovation and development of China's pharmaceutical industry.
In general, the state's support for local pharmaceutical companies' innovation is gradually increasing. China's innovation and research and development continue to advance, and the entire process from innovative product development to sales has created conditions for the return of multinational pharmaceutical companies. In the future, the pace of innovation and research and development in China is expected to accelerate further, and domestically produced innovative drugs are worth looking forward to.
In addition, cross-border cooperation has become the first step for Chinese pharmaceutical companies to move toward international innovation. According to industry insiders, the cost of conducting international multi-center clinical research is very high, and most pharmaceutical companies in China are still unable to afford it, so they have adopted a licensing method.
Li Yan, president of Qilu Pharmaceutical, said in an interview that the pharmaceutical industry is now in an era of accelerating competition. Some foreign superior pharmaceutical companies have entered China and some superior drugs have entered China, thus leveling the sea level of enterprise survival. If Chinese pharmaceutical companies want to establish themselves, they must unswervingly follow the path of innovation. The R&D, production and sales of enterprises must be in line with international standards.
Insiders pointed out that companies with innovative capabilities will open up market space. The research difficulty and risk of innovative drugs are huge and require huge capital investment and strong research and development strength support. Therefore, the author believes that pharmaceutical companies must make a specific strategic layout when they benefit from a good domestic environment and make bold innovations, in order to ensure that each step is stable and accurate.
Lip Scrub,Lip Exfoliator,Lush Lip Scrub,Brown Sugar Lip Scrub
Guangzhou Lingxue Cosmetics Co., Ltd , https://www.gzlxgj188.com